TICKERNERD
Menu
ASMBASMBHealthcare · Biotechnology

ASMB Stock Forecast: Assembly Biosciences, Inc. Price Predictions for 2026-2027

Last close, 14 Aug 2026
$33
+10.02% on the day

The 4 Wall Street analysts covering Assembly Biosciences, Inc. hold a median 12-month price target of $48 — +44.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 86 of 100 as at 15 Aug 2026 — inside the top quartile. Here, the model and the Street point the same way.

Market cap
$653.0M
Ticker Nerd rank
86 / 100
Median analyst target
$48
Analysts covering
4
Total return, dividends reinvested
1W
+23.5%
1M
+23.1%
YTD
−3.1%
1Y
+32.0%
From 52W high
−14.4%
From 52W low
+60.3%
$21
$39
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

ASMB stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Assembly Biosciences, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 15 Aug 2026
86 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Growth
92
Volatility
91
Quality
90
Value
89
Momentum
85
Revisions
65
Size
51
Issuance
31
Accruals
10

Growth (92): Sales and profits are climbing, and climbing faster than before.

Accruals (10): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

ASMB stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ASMB, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$20$30$40$50$60Oct 25Jan 26Apr 26Jul 26ASMBHigh $62Median $48Low $43

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says4 analysts
4 Buy0 Hold0 Sell
Low $43Median $48High $62

The green dot is the last close — the median target sits +44.2% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 2 moved their price target up and 1 moved it down.

DateFirmActionRatingTarget
15 June 2026MizuhoMaintainsOutperform$40 → $45
28 May 2026GuggenheimReiteratesBuy—
4 May 2026HC Wainwright & Co.ReiteratesBuy—
6 Apr 2026GuggenheimMaintainsBuy—
26 Mar 2026HC Wainwright & Co.ReiteratesBuy—
22 Dec 2025HC Wainwright & Co.ReiteratesBuy—
20 Nov 2025MizuhoMaintainsOutperform—
14 Oct 2025HC Wainwright & Co.ReiteratesBuy—
24 Sept 2025JMP SecuritiesInitiatesMarket Outperform—
8 Sept 2025GuggenheimMaintainsBuy—
18 Aug 2025HC Wainwright & Co.AssumesBuy$50
25 Mar 2025GuggenheimInitiatesBuy—
24 Mar 2025HC Wainwright & Co.ReiteratesNeutral—
27 Dec 2024HC Wainwright & Co.ReiteratesNeutral—
24 Sept 2024HC Wainwright & Co.ReiteratesNeutral—
20 Sept 2024JefferiesUpgradeBuy$2.00 → $35
20 June 2024HC Wainwright & Co.ReiteratesNeutral—
13 June 2024HC Wainwright & Co.ReiteratesNeutral—
1 Apr 2024HC Wainwright & Co.ReiteratesNeutral—
24 Mar 2023HC Wainwright & Co.MaintainsNeutral$2.50 → $1.50

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ASMB appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

ASMB analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
2
Analysts cutting
0
Fundamentals

Assembly Biosciences, Inc. (ASMB) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
26.6×

Cheaper than 30% of US stocks

Price / sales
9.0×

Cheaper than 16% of US stocks

Price / book
2.6×

Cheaper than 39% of US stocks

EV / EBITDA
−40.6×

Cheaper than 93% of US stocks

Growth & margins
Revenue growth (YoY)
38.9%

Higher than 83% of US stocks

Earnings growth (YoY)
−12.8%

Higher than 24% of US stocks

Gross margin
—
Operating margin
−47.4%

Higher than 17% of US stocks

Net margin
−0.1%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−0.0%

Higher than 44% of US stocks

Return on assets
−2.7%

Higher than 35% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

ASMB vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
ASMBAssembly Biosciences, Inc.$653.0M
86
TECXTectonic Therapeutic, Inc.$653.4M
52
SGMTSagimet Biosciences, Inc.$645.5M
30
ZVRAZevra Therapeutics, Inc.$664.6M
97
MDXGMiMedx Group, Inc.$634.4M
74
CBIOCrescent Biopharma, Inc.$633.5M
55
ALLOAllogene Therapeutics, Inc.$679.1M
79

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Assembly Biosciences, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest ASMB news & analysis

Assembly Biosciences: Gilead Advancements For GS-1179 And ABI-6250 Is A Bullish Signal

Seeking Alpha · 16 Aug 2026positive

Assembly Biosciences is maintained at a 'Buy' rating, supported by pipeline advancement and a strong cash position. Key catalysts include phase 2 trials for GS-1179 in genital herpes and ABI-6250 in chronic HDV, PBC, and PSC, with multiple readouts expected in 2027–2028, while its Gilead partnership on GS-1179 offers strategic optionality between milestone/royalty payments or a 40% cost-profit share.

Why it matters — ASMB watchers would care because upcoming phase 2 data for GS-1179 and ABI-6250 and the Gilead partnership structure represent key pipeline catalysts and strategic value drivers for the company.

Assembly Biosciences (ASMB) Reports Q2 Loss, Beats Revenue Estimates

Zacks Investment Research · 13 Aug 2026positive

Assembly Biosciences reported a Q2 loss of $0.20 per share, narrower than the Zacks Consensus Estimate of a $0.70 loss and an improvement from the $1.33 per share loss in the same quarter last year. Revenue also exceeded expectations.

Why it matters — The better-than-expected quarterly results show the company outperformed analyst forecasts on both earnings and revenue, marking a notable improvement from the prior year.

Assembly Biosciences Reports Second Quarter 2026 Financial Results and Recent Updates

GlobeNewsWire · 13 Aug 2026positive

Assembly Biosciences reported its second quarter 2026 financial results and provided a business update, highlighting the expansion of ABI-6250 clinical development into cholestatic liver diseases such as primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC).

Why it matters — The expansion of ABI-6250 into new liver disease indications broadens the company's clinical pipeline and targets larger patient populations.

FAQ

Frequently asked questions about ASMB stock

What is the ASMB stock price forecast for 2026-2027?

The 4 Wall Street analysts covering Assembly Biosciences, Inc. have a median 12-month price target of $48, with estimates ranging from $43 to $62. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is ASMB stock a buy right now?

Of the 4 analysts covering Assembly Biosciences, Inc., 4 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Assembly Biosciences, Inc. 86 out of 100 across roughly 4,600 US stocks as at 15 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ASMB?

As at 15 Aug 2026, Assembly Biosciences, Inc. ranks 86 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (92 of 100).

Will ASMB stock go up?

No one can know that. What the data says: the median 12-month target from 4 analysts implies +44.2% from the last close, and Ticker Nerd's factor model ranks Assembly Biosciences, Inc. 86 out of 100 as at 15 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the ASMB stock forecast for 2030?

No analyst covering Assembly Biosciences, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ASMB are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $43 to $62 over the next 12 months.

How has ASMB stock performed over the past year?

Assembly Biosciences, Inc. returned +32.0% over the 12 months to 14 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Assembly Biosciences, Inc. do?

Assembly Biosciences Inc. is a clinical-stage biotechnology company focused on developing novel antiviral therapeutics for serious viral diseases worldwide.

What is the latest news on ASMB?

The most recent item we track (Seeking Alpha, 16 Aug 2026): "Assembly Biosciences: Gilead Advancements For GS-1179 And ABI-6250 Is A Bullish Signal". Assembly Biosciences is maintained at a 'Buy' rating, supported by pipeline advancement and a strong cash position. Key catalysts include phase 2 trials for GS-1179 in genital herpes and ABI-6250 in chronic HDV, PBC, and PSC, with multiple readouts expected in 2027–2028, while its Gilead partnership on GS-1179 offers strategic optionality between milestone/royalty payments or a 40% cost-profit share.

Company

About Assembly Biosciences, Inc.

Assembly Biosciences Inc. is a clinical-stage biotechnology company focused on developing novel antiviral therapeutics for serious viral diseases worldwide. Its pipeline features long-acting helicase-primase inhibitors ABI-5366 and ABI-1179, currently in Phase 1a/1b clinical studies targeting recurrent genital herpes caused by herpes simplex virus. The company is also advancing ABI-4334, a next-generation capsid assembly modulator in Phase 1b trials designed to disrupt the hepatitis B virus replication cycle, and ABI-6250, an oral hepatitis delta virus entry inhibitor in Phase 1a studies. Additional candidates include ABI-7272, a broad-spectrum non-nucleoside polymerase inhibitor for transplant-related herpesviruses. Assembly Biosciences Inc. leverages expertise in virology to create innovative oral therapies aimed at improving treatment outcomes for patients with chronic viral infections like hepatitis B and delta, as well as herpesviruses. Founded in 2005 and headquartered in South San Francisco, California, the company plays a key role in the biotechnology sector by addressing unmet needs in antiviral drug development.

CEO Mr. Jason A. Okazaki J.D. · 73 employees · United States · https://www.assemblybio.com